arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Bone Biologics Corp

BBLG
$0.53 ▲ +0.06 (+12.32%) at close
Healthcare ·Orthopedic, Prosthetic & Surgical Appliances & Supplies ·USOrthopedic, Prosthetic & Surgical Appliances & Supplies
78 Visible periods
28 Metrics
Peer-ranked Benchmarks
Price Chart
27
Health
Poor
Bearish
auto_awesome

Analytical Summary

Bone Biologics Corp faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap
Dividend Yield
Revenue Growth None
Op. Margin None
ROIC -16.3%
FCF / Share $-0.29
Trailing P/E
Price / Book 0.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 23, 2026.

78-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$0.00
↓ -100.0%
Net Income Profit after all expenses
$-765.99K
↑ +24.7%
Operating Margin Operating profit as % of sales
-0.0%
↑ +46.8%
FCF / Share Free cash flow per share
$-0.29
↑ +35.6%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
15
Cash Quality
58

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 19 years · 78 quarters